1. A composition comprising CRF and an angiogenesis inhibitor for use in preventing the progression of a tumor in a patient of a person suffering from cancer. The composition of claim 1, wherein the angiogenesis inhibitor is bevacizumab (Avastin®). The composition of claim 1, wherein the angiogenesis inhibitor is sunitinib malate (Sutent®). A composition according to any one of claims 1 to 3, wherein the CRF and the angiogenesis inhibitor are prepared for administration individually or simultaneously. The composition of claim 1, wherein the cancer is colon or rectal cancer, metastatic colorectal cancer, lung cancer, non-squamous non-small cell lung cancer, breast cancer, metastatic breast cancer, metastatic HER2-negative breast cancer, brain cancer, glioblastoma adults, children glioblastoma, children’s resistant glioblastoma, glioma, ependymoma, astrocytoma, medulloblastoma, medulloblastoma of children, neuroglioma, oligodendroglioma or meningioma, kidney cancer, such as advanced renal ductal carcinoma, bladder cancer, cervical cancer, colon cancer (which includes colorectal cancer), esophageal cancer, stomach cancer, head and neck cancer, liver cancer, lung cancer (both small cell and non-small cell), squamous non-small cell cancer lung, melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma (which includes osteosarcoma), skin cancer (which includes squamous cell carcinoma), stomach cancer, testicular cancer, thyroid cancer, uterine cancer, mesothelioma , cholangioc arcinoma, leiomyosarcoma, liposarcoma, nasopharyngeal, neuroendocrine carcinoma, ovarian carcinoma1. Композиция, содержащая CRF и ингибитор ангиогенеза, для применения в предотвращении прогрессирования опухоли у пациента человека, страдающего раком.2. Композиция по п.1, где ингибитор ангиогенеза представляет собой бевацизумаб (Avastin®).3. Композиция по п.1, где ингибитор ангиогенеза представляет собой сунитиниба малат (Sutent®).4. Композиция по любому из пп.1-3,
